S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Advisor to FBI: Sell META now (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Advisor to FBI: Sell META now (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Advisor to FBI: Sell META now (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Advisor to FBI: Sell META now (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Advisor to FBI: Sell META now (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Advisor to FBI: Sell META now (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Advisor to FBI: Sell META now (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Advisor to FBI: Sell META now (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Leading Egyptian opposition politician targeted with spyware, researchers find
NASDAQ:BLRX

BioLineRx (BLRX) Stock Forecast, Price & News

$2.07
+0.09 (+4.55%)
(As of 09/22/2023 ET)
Compare
Today's Range
$1.99
$2.12
50-Day Range
$1.23
$2.45
52-Week Range
$0.55
$2.53
Volume
458,008 shs
Average Volume
2.62 million shs
Market Capitalization
$127.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

BioLineRx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
914.5% Upside
$21.00 Price Target
Short Interest
Healthy
3.90% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of BioLineRx in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.83) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

615th out of 965 stocks

Pharmaceutical Preparations Industry

282nd out of 456 stocks


BLRX stock logo

About BioLineRx (NASDAQ:BLRX) Stock

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.

BLRX Price History

BLRX Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BLRX: …Go!
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BioLineRx rallies on FDA approval of Aphexda with Filgrastim
BLRX: On Your Marks, Get Set…
BioLineRx GAAP EPS of -$0.02
BioLineRx (BLRX) Earnings Dates & Reports
BLRX: First Quarter Results
biolinerx Q1 2023 Earnings Preview
See More Headlines
Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Company Calendar

Last Earnings
8/30/2023
Today
9/24/2023
Next Earnings (Estimated)
11/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLRX
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+914.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.83 per share

Miscellaneous

Free Float
60,854,000
Market Cap
$127.37 million
Optionable
Not Optionable
Beta
1.80
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Philip A. Serlin CPA (Age 63)
    M.B.A., CPA, MBA, Chief Exec. Officer
    Comp: $635k
  • Ms. Mali Zeevi CPA (Age 47)
    CPA, Chief Financial Officer
    Comp: $380k
  • Dr. Ella Sorani (Age 55)
    Chief Devel. Officer
    Comp: $457k
  • Ms. Holly W. May M.B.A. (Age 61)
    Pres of BioLineRx USA
    Comp: $328k
  • Mr. John Lacey
    Head of Corp. Communications & Investor Relations
  • Mr. Adam Janoff Esq.
    Gen. Counsel & Head of Compliance
  • Ms. Tsipi Keren-Lehrer B.Sc.
    L.L.B., Head of BD & Strategic Advisor
  • Dr. Tami Rachmilewitz M.D. (Age 52)
    Chief Medical Officer
  • Mr. Raziel Fried
    Treasurer & Budgetary Control Director













BLRX Stock - Frequently Asked Questions

Should I buy or sell BioLineRx stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BLRX shares.
View BLRX analyst ratings
or view top-rated stocks.

What is BioLineRx's stock price forecast for 2023?

1 equities research analysts have issued 12-month price objectives for BioLineRx's stock. Their BLRX share price forecasts range from $21.00 to $21.00. On average, they predict the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 914.5% from the stock's current price.
View analysts price targets for BLRX
or view top-rated stocks among Wall Street analysts.

How have BLRX shares performed in 2023?

BioLineRx's stock was trading at $0.59 at the beginning of 2023. Since then, BLRX stock has increased by 250.8% and is now trading at $2.07.
View the best growth stocks for 2023 here
.

When is BioLineRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our BLRX earnings forecast
.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) released its earnings results on Wednesday, August, 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.14. During the same quarter in the prior year, the business earned ($0.16) earnings per share.

What other stocks do shareholders of BioLineRx own?
What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

Who are BioLineRx's major shareholders?

BioLineRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include LPL Financial LLC (0.20%), Renaissance Technologies LLC (0.16%), Envestnet Asset Management Inc. (0.11%), PVG Asset Management Corp (0.10%), Osaic Holdings Inc. (0.03%) and Osaic Holdings Inc. (0.03%).

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLineRx's stock price today?

One share of BLRX stock can currently be purchased for approximately $2.07.

How much money does BioLineRx make?

BioLineRx (NASDAQ:BLRX) has a market capitalization of $127.37 million. The biotechnology company earns $-24,950,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How can I contact BioLineRx?

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The official website for the company is www.biolinerx.com. The biotechnology company can be reached via phone at (728) 642-9100, via email at ir@biolinerx.com, or via fax at 972-8642-9101.

This page (NASDAQ:BLRX) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -